Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab and Trilaciclib in Advanced NSCLC
NCT05910034Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Nanobodies (VHH), Monoclonal Antibodies
01
Overview
A Phase 2 trial of envafolimab, trilaciclib in non-small cell lung cancer (NSCLC), sponsored by Fudan University. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
envafolimabtrilaciclib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05910034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05910034.